NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
63187-0526-12 | 63187-0526 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 20, 2023 | In Use | |
60505-6096-00 | 60505-6096 | Bendamustine hydrochloride | Bendamustine Hydrochloride | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jun 19, 2023 | Apr 30, 2025 | In Use |
60505-6095-00 | 60505-6095 | Bendamustine Hydrochloride | Bendamustine Hydrochloride | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Jun 19, 2023 | Apr 30, 2025 | In Use |
50242-0125-01 | 50242-0125 | Glofitamab | Columvi | 2.5 mg/2.5mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Jun 15, 2023 | In Use | |
25021-0465-01 | 25021-0465 | Octreotide acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 15, 2023 | In Use | ||
25021-0251-50 | 25021-0251 | Mitomycin | Mitomycin | 20.0 mg/40mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 15, 2023 | In Use | |
25021-0463-01 | 25021-0463 | Octreotide acetate | Octreotide Acetate | 50.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 15, 2023 | In Use | ||
25021-0464-01 | 25021-0464 | Octreotide acetate | Octreotide Acetate | 100.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 15, 2023 | In Use | ||
25021-0466-05 | 25021-0466 | Octreotide acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 15, 2023 | In Use | ||
50242-0127-01 | 50242-0127 | Glofitamab | Columvi | 10.0 mg/10mL | Immunotherapy | Monoclonal Antibody | CD20, CD3 | Intravenous | Jun 15, 2023 | In Use | |
25021-0250-20 | 25021-0250 | Mitomycin | Mitomycin | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 15, 2023 | In Use | |
25021-0467-05 | 25021-0467 | Octreotide acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 15, 2023 | In Use | ||
25021-0252-51 | 25021-0252 | Mitomycin | Mitomycin | 40.0 mg/80mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | Jun 15, 2023 | In Use | |
68083-0516-01 | 68083-0516 | Octreotide Acetate | Octreotide Acetate | 1000.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 13, 2023 | In Use | ||
68083-0515-01 | 68083-0515 | Octreotide Acetate | Octreotide Acetate | 200.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Jun 13, 2023 | In Use | ||
72266-0152-01 | 72266-0152 | Zoledronic acid | Zoledronic acid | 5.0 mg/100mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jun 12, 2023 | In Use | ||
70377-0012-11 | 70377-0012 | Everolimus | EVEROLIMUS | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
71335-9715-01 | 71335-9715 | PREDNISONE | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 8, 2023 | In Use | |
70377-0011-11 | 70377-0011 | Everolimus | EVEROLIMUS | 5.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
70377-0010-11 | 70377-0010 | Everolimus | EVEROLIMUS | 2.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
70377-0013-11 | 70377-0013 | Everolimus | EVEROLIMUS | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Jun 8, 2023 | In Use | |
72189-0489-07 | 72189-0489 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 7, 2023 | In Use | |
70121-2461-01 | 70121-2461 | Pemetrexed disodium | PEMRYDI RTU | 500.0 mg/50mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jun 6, 2023 | In Use | |
60505-6277-00 | 60505-6277 | CISplatin | CISplatin | 50.0 mg/50mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 6, 2023 | In Use | |
70121-2453-01 | 70121-2453 | Pemetrexed disodium | PEMRYDI RTU | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Jun 6, 2023 | In Use |
Found 11465 results — Export these results